MYRIAD GENETICS Inc. established a Tumor BRACAnalysis CDx laboratory in Munich.
The test is a companion diagnostic used to identify patients with BRAC mutations who may benefit from treatment with PARP inhibitors, such as olaparib, a novel PARP inhibitor being developed by AstraZeneca.
The European Medicines Agency’s Committee for Medicinal Products for Human Use recently recommended marketing authorization for olaparib as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
